Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label StudyDemonstrated Clinical Benefits from QRX003 Observed Across All Measured EndpointsBefore and After Dosing with QRX003 Photographs Available for Review On WebsiteNo Product Safety Concerns Identified in Any Quoin Netherton Study to Date ASHBURN, Va., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmace ...